Abstracts & posters
1. Predictive role of PSMA-1007 PET parameters in biochemical recurrence-free survival in high-risk prostate cancer patients receiving neoadjuvant hormonal treatment
Niloefar Ahmadi Bidakhvidi, University Hospitals Leuven, Leuven, Belgium
2. Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?
Alexander Decruyenaere, Ghent University Hospital, Ghent, Belgium
3. Pelvic organ-preserving surgery in female with bladder cancer
Antoine Delmarche, Cliniques universitaires Saint-Luc, Brussels, Belgium
4. Characteristics, treatment patterns and clinical outcomes for patients with non-muscle invasive bladder cancer in Belgium: the BLABEL study
Lise De Smedt, Medical Affairs Department, MSD Belgium, Brussels, Belgium
5. PSMA PET/CT Stage Migration and Genomic Classifier Scores in High-Risk Prostate Cancer: First-Year Results from the THUNDER Trial (NCT06282588)
Fleur Kleiburg, Iridium Network, Antwerp, Belgium
6. Testis to Phallus : Phallic Reconstruction Using the Right Testis Following Cystoprostatectomy and Penectomy for Urethral Cancer
Georges Mjaess, Cliniques Universitaires Saint-Luc, Brussels, Belgium
7. Magnetic Resonance Imaging-Targeted Biopsy and Accuracy with Radical Prostatectomy Specimens: A Grading Issue
Myky Nguyen, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
8. ProstACT Global: A phase 3 study of Lutetium (Lu177) rosopatamab tetraxetan plus standard of care vs standard of care alone in patients with metastatic castration-resistant prostate cancer
Jess Roetman, Telix Pharmaceuticals
Abstract submission is now closed.
Abstracts are currently being reviewed by the board.
Out of the submitted abstracts, the BMUC board will select 1 winner to give a presentation during the plenary poster contest session.
In any case: if your abstract is approved, your poster will be published online and you are invited to bring the printed version to the meeting. For every abstract that is submitted, at least one of the authors must be present during the meeting. Please note that the first author needs to be working in Belgium.
Review
Abstracts submitted before the deadline of 28 April 2025 will be reviewed by the BMUC board. Within 10 days after the submission deadline, the author will be notified whether the abstract has been accepted or not. The winner will receive a separate email at a later stage.
Approval
If your abstract is approved by the board, you can submit your e-poster in PDF format by sending it to info@bmuc.be.
Format: A1 size, portrait style. Please bring a printed version of the poster with you to the meeting on 16 & 17 May 2025. Poster boards and material to hang the poster will be provided by the organisation.
If you need to withdraw your abstract, a written statement describing the reasons for the withdrawal must be sent to info@bmuc.be
Posters will be published on the BMUC website and will be visible for all website visitors.
Winning abstract
The winning abstract submitter will receive a separate email at a later stage with more information on the poster contest with oral presentation during the main scientific programme on Saturday 17 May 2025.